title: Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children.
abstract: We report a retrospective analysis on 46 pediatric patients (median age 9 years, range 1-17 years) with non-Hodgkin's lymphoma (NHL), transplanted in six Spanish centers. Fourteen patients underwent allogeneic bone marrow transplantation (BMT) and 32 autologous BMT. Most patients were boys (36 of 46). Twenty one cases were of lymphoblastic lymphoma, 19 Burkitt's lymphoma and six diffuse large cell lymphoma. Maximal Murphy's stage any time before BMT was stage III in 17 cases and stage IV in 29 cases. At BMT, 13 cases were in first CR, 21 in second CR, seven in third CR, four with sensitive active disease and one with refractory disease. All patients transplanted in CRl were considered candidates for BMT because of delayed CR (two cases), failure of the first-line therapy (seven cases) or central nervous system (CNS) or BM infiltration at diagnosis (four cases). Conditioning therapy included TBI in 33 patients and 13 cases were conditioned with chemotherapy alone. Toxic mortality was 13% (three of 14 in the allogeneic BMT group and three of 32 in the autologous group). No toxic deaths were registered in 13 patients undergoing BMT in CR1 (three allogeneic BMT and ten autologous BMT). Twelve patients relapsed 1-7 months after BMT. Overall event-free survival (EFS) was 58% (42-73%; confidence interval (CI) 95%), with a median follow-up of 33 months. EFS was similar for allogeneic BMT and autologous patients. Disease status at BMT was the only predictive factor for EFS (P < 0.01). There were no significant differences between patients in CR1 (82.5%) and CR2 (68%).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hospital Universitario Marques de Valdecilla Servicio de Hematología, Santander, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Bureo
authors.forename: J J
authors.initials: JJ
authors.lastname: Ortega
authors.forename: A
authors.initials: A
authors.lastname: Muñoz
authors.forename: J
authors.initials: J
authors.lastname: Cubells
authors.forename: L
authors.initials: L
authors.lastname: Madero
authors.forename: A
authors.initials: A
authors.lastname: Verdaguer
authors.forename: J
authors.initials: J
authors.lastname: Baro
authors.forename: T
authors.initials: T
authors.lastname: Olivé
authors.forename: M S
authors.initials: MS
authors.lastname: Maldonado
authors.forename: N
authors.initials: N
authors.lastname: Pardo
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation; D002051:Burkitt Lymphoma / Q000097:blood / Q000401:mortality / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000401:mortality / Q000628:therapy*; D008297:Male; D015999:Multivariate Analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate